Systemic and Radiation Treatments: Managing the Cells

When managing the cells themselves in Diffuse Leptomeningeal Melanocytosis (DLM) or Neurocutaneous Melanosis (NCM), your medical team is navigating a landscape without a single, proven “standard of care” ^[1][2]. Because these conditions are ultra-rare, doctors often look to therapies used in skin melanoma or other rare brain cancers, tailoring them to the specific genetic makeup of the cells ^[3].

It is important to be honest: while some treatments show promise in individual cases, the disease remains highly aggressive, and the primary goal is often to stabilize the condition or provide meaningful time with improved symptoms ^[1][4].

Targeted Therapies: Blocking the Growth Path

The most significant advance in treating these conditions has been the experimental use of targeted therapies. These are drugs designed to “turn off” the specific genetic switches that tell the pigment cells to multiply.

• MEK Inhibitors (e.g., Trametinib): If the cells have an NRAS mutation, they rely on a pathway called MAPK to grow. MEK inhibitors like trametinib block a key part of this pathway ^[4]. In a small study of four children with this mutation, all showed some improvement in symptoms, with one child remaining symptom-free for nine months before the disease progressed ^[4].
• Combination Approaches: Some researchers have seen more durable results by combining trametinib with other drugs, such as azacitidine. In one remarkable case, an infant with NCM had a significant reduction in brain thickening and was meeting developmental milestones over four years later while staying on the medication ^[5][6].

It is important to note that these are small case reports, generally off-label, and do not establish a standard of care. Furthermore, finding an NRAS, GNAQ, or GNA11 mutation does not guarantee a drug will work, and these medications carry significant toxicities.

Immunotherapy: Engaging the Immune System

Immunotherapy uses the body’s own immune system to recognize and attack the melanocytes. These drugs, known as checkpoint inhibitors, have revolutionized the treatment of typical skin melanoma and are now being used in DLM, though evidence in primary DLM borrows heavily from metastatic melanoma experience.

• PD-1 Inhibitors (e.g., Pembrolizumab, Nivolumab): These drugs help “unmask” the tumor cells so the immune system can find them ^[7].
• Mixed Results: Evidence for immunotherapy in DLM is based on individual reports. One adult patient remained stable for two years on pembrolizumab ^[7], while other patients saw only temporary benefits or did not respond at all ^[8][9]. Some centers are now exploring intrathecal delivery—injecting the drug directly into the spinal fluid—to help it reach the brain more effectively, which has shown promise in early, small groups ^[10]. However, intrathecal delivery carries distinct procedure-specific and immune-related risks, and should be carefully evaluated at an expert center or within a clinical trial.

The Role of Chemotherapy

Traditional chemotherapy, which attacks all fast-growing cells, is generally considered less effective for DLM than targeted or immune therapies ^[11]. However, it is still used in some cases, often in combination with other treatments ^[12].

• Systemic vs. Intrathecal: Chemotherapy can be given through an IV (systemically) or directly into the spinal fluid (intrathecal or intraventricular). While some retrospective studies have associated chemotherapy with slightly longer survival times in pooled data, these observational associations are highly vulnerable to selection bias and do not prove treatment efficacy, making it rarely used as a standalone treatment today ^[1][13].

Radiation Therapy: Stabilizing and Relieving Symptoms

Radiation uses high-energy beams to damage the DNA of the pigment cells. In DLM, it is rarely used as a “cure” but can be a powerful tool for stabilization or palliative care (relief of symptoms) ^[14].

• Craniospinal Irradiation (CSI): Because DLM is “diffuse” (spread out), doctors may consider radiating the entire brain and spinal cord for progressive disease ^[3]. This has helped some children regain the ability to walk or attend school temporarily by reducing the “burden” of cells in the nervous system ^[15].
• Focal Radiation: If there is a single, large “nodule” or tumor causing specific problems (like weakness in one arm), radiation can be aimed specifically at that spot ^[16].

Radiation carries risks, especially for young children, including potential severe neurocognitive deficits, endocrine failure, stunted growth, marrow suppression, and the risk of secondary cancers later in life. Your team will weigh these major trade-offs against the need to control the disease’s immediate threats ^[3].

A Highly Individualized Path

Because there are no large clinical trials to tell doctors exactly which drug to give and when, your care team may suggest a “multimodal” approach—using a combination of surgery, targeted drugs, and perhaps radiation ^[2][13]. Decisions are often made through a molecular tumor board, where experts from different fields look at the specific mutations in the cells to find the best possible match among available treatments ^[2].